Advertisement

Chronic Migraine

Diagnosis and Management
Published:October 31, 2022DOI:https://doi.org/10.1016/j.ncl.2022.05.005

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Neurologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dodick D.W.
        • Loder E.W.
        • Manack Adams A.
        • et al.
        Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study.
        Headache. 2016; 56: 821-834
        • Steiner T.J.
        • Stovner L.J.
        • Jensen R.
        • et al.
        Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019.
        J Headache Pain. 2020; 21: 137
        • Reuter U.
        GBD 2016: still no improvement in the burden of Migraine.
        Lancet Neurol. 2018; 17: 929-930
        • Natoli J.L.
        • Manack A.
        • Dean B.
        • et al.
        Global prevalence of chronic migraine: a systematic review.
        Cephalalgia. 2009; 30: 599-609
        • Buse D.C.
        • Manack A.N.
        • Fanning K.M.
        • et al.
        Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American migraine prevalence and Prevention Study.
        Headache. 2012; 52: 1456-1470
        • Bigal M.E.
        • Serrano D.
        • Buse D.
        • et al.
        Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.
        Headache. 2008; 48: 1157-1168
        • Burch R.C.
        • Buse D.C.
        • Lipton R.B.
        Migraine.
        Neurol Clin. 2019; 37: 631-649
        • Manack A.
        • Buse D.C.
        • Serrano D.
        • et al.
        Rates, Predictors, and consequences of remission from chronic migraine to episodic migraine.
        Neurology. 2011; 76: 711-718
      1. Headache classification committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd Edition.
        Cephalalgia. 2018; 38: 1-211
        • May A.
        • Schulte L.H.
        Chronic migraine: risk factors, mechanisms and treatment.
        Nat Rev Neurol. 2016; 12: 455-464
        • Buse D.C.
        • Greisman J.D.
        • Baigi K.
        • et al.
        Migraine progression: a systematic review.
        Headache. 2019; 59: 306-338
        • Robblee J.
        • Starling A.J.
        Seeds for success: lifestyle Management in Migraine.
        Cleve Clin J Med. 2019; 86: 741-749
        • Lipton R.B.
        • Fanning K.M.
        • Serrano D.
        • et al.
        Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine.
        Neurology. 2015; 84: 688-695
        • Lipton R.B.
        • Stewart W.F.
        • Stone A.M.
        • et al.
        Stratified care vs step care strategies for migraine: the disability in strategies of care (DISC) study: a randomized trial.
        JAMA. 2000; 284: 2599-2605
        • Goadsby P.J.
        • Wietecha L.A.
        • Dennehy E.B.
        • et al.
        Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of Migraine.
        Brain. 2019; 142: 1894-1904
        • Kuca B.
        • Silberstein S.D.
        • Wietecha L.
        • et al.
        Lasmiditan is an effective acute treatment for migraine.
        Neurology. 2018; 91: e2222-e2232
        • Wilbraham D.
        • Berg P.H.
        • Tsai M.
        • et al.
        Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study.
        J Clin Pharmacol. 2019; 60: 495-504
        • Rau J.C.
        • Navratilova E.
        • Oyarzo J.
        • et al.
        Evaluation of ly573144 (lasmiditan) in a preclinical model of medication overuse headache.
        Cephalalgia. 2020; 40: 903-912
        • Lipton R.B.
        • Dodick D.W.
        • Ailani J.
        • et al.
        Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of Migraine.
        JAMA. 2019; 322: 1887
        • Croop R.
        • Goadsby P.J.
        • Stock D.A.
        • et al.
        Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of Migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
        The Lancet. 2019; 394: 737-745
        • Dodick D.W.
        • Lipton R.B.
        • Ailani J.
        • et al.
        Ubrogepant for the treatment of Migraine.
        N Engl J Med. 2019; 381: 2230-2241
        • Lipton R.B.
        • Dodick D.W.
        • Goadsby P.J.
        • et al.
        Within-person analysis of ubrogepant treatment of mild versus moderate-severe headache pain during a phase 3 long-term safety extension trial (S31.006).
        Neurology. 2022; 98: 167
        • Berman G.
        • Croop R.
        • Kudrow D.
        • et al.
        Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for Migraine. Headache.
        J Head Face Pain. 2020; 60: 1734-1742
        • Mulder I.A.
        • Li M.
        • Vries T.
        • et al.
        Anti-migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice.
        Ann Neurol. 2020; 88: 771-784
        • Chowdhury D.
        • Bansal L.
        • Duggal A.
        • et al.
        TOP-PRO Study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.
        Cephalalgia. 2022; 42: 396-408
        • Jackson J.L.
        • Kuriyama A.
        • Kuwatsuka Y.
        • et al.
        Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.
        PLoS One. 2019; 14: e0212785
        • Lai K.L.
        • Niddam D.M.
        • Fuh J.L.
        • et al.
        Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial.
        Acta Neurol Scand. 2017; 135: 476-483
        • Sánchez-Rodríguez C.
        • Sierra A.
        • Planchuelo-Gómez A.
        • et al.
        Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study.
        Scientific Rep. 2021; 11: 3846
        • Silberstein S.D.
        Preventive migraine treatment.
        Continuum. 2015; 21: 973-989
        • Ailani J.
        • Burch R.C.
        • Robbins M.S.
        The american headache society consensus statement: update on integrating new migraine treatments into clinical practice.
        Headache. 2021; 61: 1021-1039
        • Schwedt T.J.
        Chronic migraine.
        BMJ. 2014; 348https://doi.org/10.1136/bmj.g1416
        • Diener H.-C.
        • Dodick D.
        • Goadsby P.
        • et al.
        Chronic migraine--classification, characteristics and Treatment.
        Nat Rev Neurol. 2012; 8: 162-171
        • Silberstein S.D.
        • Lipton R.
        • Dodick D.
        • et al.
        Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
        Headache. 2007; 47: 170-180
        • Diener H.C.
        • Bussone G.
        • Oene J.V.
        • et al.
        Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
        Cephalalgia. 2007; 27: 814-823
        • Burch R.
        Preventive migraine treatment.
        Continuum. 2021; 27: 613-632
        • D’Amico D.
        Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials.
        Neurol Sci. 2010; 31: 23-28
        • Yurekli V.A.
        • Akhan G.
        • Kutluhan S.
        • et al.
        The effect of sodium valproate on chronic daily headache and its subgroups.
        J Headache Pain. 2008; 9: 37-41
        • Spira P.J.
        • Beran R.G.
        Gabapentin in the prophylaxis of chronic daily headache.
        Neurology. 2003; 61: 1753-1759
        • Calandre E.P.
        • Garcia-Leiva J.M.
        • Rico-Villademoros F.
        • et al.
        Pregabalin in the treatment of chronic migraine: an open-label study.
        Clin Neuropharmacol. 2010; 33: 35-39
        • Belvis R.
        • Aceituno A.
        • Martinez-Corral M.
        Zonisamide is effective in the preventive therapy of chronic migraine: doc 551.
        J Headache Pain. 2013; 14: 1
        • Villani V.
        • Ciuffoli A.
        • Prosperini L.
        • et al.
        Zonisamide for migraine prophylaxis in topiramate-intolerant patients: An observational study.
        Headache. 2011; 51: 287-291
        • Bermejo P.E.
        • Dorado R.
        Zonisamide for migraine prophylaxis in patients refractory to topiramate.
        Clin Neuropharmacol. 2009; 32: 103-106
        • Jion Y.I.
        • Raff A.
        • Grosberg B.M.
        • et al.
        The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension.
        Headache. 2015; 55: 161-166
        • Couch J.R.
        Amitriptyline in the prophylactic treatment of migraine and chronic daily headache.
        Headache. 2011; 51: 33-51
        • Doyle Strauss L.
        • Weizenbaum E.
        • Loder E.W.
        • et al.
        Amitriptyline dose and treatment outcomes in specialty headache practice: a retrospective cohort study.
        Headache. 2016; 56: 1626-1634
        • Volpe F.M.
        An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache.
        J Clin Psychiatry. 2008; 69: 1449-1454
        • Young W.B.
        • Bradley K.C.
        • Anjum M.W.
        • et al.
        Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study.
        Headache. 2013; 53: 1430-1437
        • Dorosch T.
        • Ganzer C.A.
        • Lin M.
        • et al.
        Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults.
        Curr Pain Headache Rep. 2019; 23: 85-88
        • Rau J.C.
        • Dodick D.W.
        Other preventive anti-migraine treatments: ACE inhibitors, ARBS, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists.
        Curr Treat Options Neurol. 2019; 21: 17
        • Stovner L.J.
        • Linde M.
        • Gravdahl G.B.
        • et al.
        A comparative study of Candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study.
        Cephalalgia. 2013; 34: 523-532
        • Messina R.
        • Lastarria Perez C.P.
        • Filippi M.
        • et al.
        Candesartan in migraine prevention: results from a retrospective real-world study.
        J Neurol. 2020; 267: 3243-3247
        • Edvardsson B.
        Atenolol in the Prophylaxis of Chronic Migraine: a 3-Month Open-Label Study.
        SpringerPlus. 2013; 2: 479
        • Silberstein S.D.
        • Peres M.F.P.
        • Hopkins M.M.
        • et al.
        Olanzapine in the treatment of refractory migraine and chronic daily headache.
        Headache. 2002; 42: 515-518
        • Saper J.R.
        • Lake III, A.E.
        • Cantrell D.T.
        • et al.
        Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.
        Headache. 2002; 42: 470-482
        • Huang L.
        • Bocek M.
        • Jordan J.K.
        • et al.
        Memantine for the prevention of primary headache disorders.
        Ann Pharmacother. 2014; 48: 1507-1511
        • Goadsby P.J.
        • Dodick D.W.
        • Ailani J.
        • et al.
        Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2B/3 trial.
        Lancet Neurol. 2020; 19: 727-737
      2. Abbvie. Press release. AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine.
        (Available at:) (Accessed March 10, 2022)
        • Silberstein S.D.
        • Holland S.
        • Freitag F.
        • et al.
        Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults.
        Neurology. 2012; 78: 1337-1345
        • Simpson D.M.
        • Hallett M.
        • Ashman E.J.
        • et al.
        Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache.
        Neurology. 2016; 86: 1818-1826
        • Do T.P.
        • Guo S.
        • Ashina M.
        Therapeutic novelties in Migraine: new drugs, new hope?.
        J Headache Pain. 2019; 20: 37
        • Brandes J.L.
        • Diener H.-C.
        • Dolezil D.
        • et al.
        The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
        Cephalalgia. 2019; 40: 28-38
        • Ashina M.
        • Goadsby P.J.
        • Reuter U.
        • et al.
        Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
        Cephalalgia. 2019; 39: 1455-1464
        • Tepper S.J.
        History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from Translational Research to treatment.
        Headache. 2018; 58: 238-275
        • Evans R.W.
        Raynaud's phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists.
        Headache. 2019; 59: 1360-1364
        • Breen I.D.
        • Brumfield C.M.
        • Patel M.H.
        • et al.
        Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with raynaud phenomenon.
        JAMA Netw Open. 2021; 4: e217934
        • Schwedt T.
        • Reuter U.
        • Tepper S.
        • et al.
        Early onset of efficacy with erenumab in patients with episodic and chronic migraine.
        J Headache Pain. 2018; 19: 92
        • Rayhill M.
        Headache in pregnancy and lactation.
        Continuum (Minneap Minn). 2022; 28: 72-92
        • Tinsley A.
        • Rothrock J.F.
        Safety and tolerability of preventive treatment options for chronic migraine.
        Expert Opin Drug Saf. 2021; 20: 1523-1533
        • Lipton R.B.
        • Goadsby P.J.
        • Smith J.
        • et al.
        Efficacy and safety of eptinezumab in patients with chronic migraine.
        Neurology. 2020; 94: e1365-e1377
        • Ray J.C.
        • Walter S.
        • Rapoport A.M.
        • et al.
        Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects.
        J Neurol Neurosurg Psychiatr. 2021; 92: 1325-1334
        • Dodick D.W.
        • Lipton R.B.
        • Silberstein S.
        • et al.
        Eptinezumab for prevention of chronic migraine: a randomized phase 2B clinical trial.
        Cephalalgia. 2019; 39: 1075-1085
        • Dodick D.W.
        • Ashina M.
        • Brandes J.L.
        • et al.
        Arise: a phase 3 randomized trial of erenumab for episodic migraine.
        Cephalalgia. 2018; 38: 1026-1037
        • Goadsby P.J.
        • Reuter U.
        • Hallström Y.
        • et al.
        A controlled trial of erenumab for episodic migraine.
        N Engl J Med. 2017; 377: 2123-2132
        • Tepper S.
        • Ashina M.
        • Reuter U.
        • et al.
        Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
        Lancet Neurol. 2017; 16: 425-434
        • Kudrow D.
        • Pascual J.
        • Winner P.K.
        • et al.
        Vascular safety of erenumab for migraine prevention.
        Neurology. 2019; 94: 1052
        • Lipton R.B.
        • Tepper S.J.
        • Reuter U.
        • et al.
        Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study.
        Neurology. 2019; 92: e2250-e2260
        • Dodick D.W.
        • Silberstein S.D.
        • Bigal M.E.
        • et al.
        Effect of fremanezumab compared with placebo for prevention of episodic migraine.
        JAMA. 2018; 319: 1999
        • Silberstein S.D.
        • Dodick D.W.
        • Bigal M.E.
        • et al.
        Fremanezumab for the preventive treatment of chronic migraine.
        N Engl J Med. 2017; 377: 2113-2122
        • Detke H.C.
        • Goadsby P.J.
        • Wang S.
        • et al.
        Galcanezumab in chronic migraine.
        Neurology. 2018; 91: e2211-e2221
        • Skljarevski V.
        • Oakes T.M.
        • Zhang Q.
        • et al.
        Effect of different doses of galcanezumab vs placebo for episodic migraine prevention.
        JAMA Neurol. 2018; 75: 187
        • Stauffer V.L.
        • Dodick D.W.
        • Zhang Q.
        • et al.
        Evaluation of galcanezumab for the prevention of episodic migraine.
        JAMA Neurol. 2018; 75: 1080
        • Frampton J.E.
        • OnabotulinumtoxinA S.S.
        A review in the prevention of chronic migraine.
        Drugs. 2018; 78: 589-600
        • Diener H.C.
        • Dodick D.W.
        • Turkel C.C.
        • et al.
        OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
        Headache. 2010; 50: 921-936
        • Silberstein S.D.
        • Dodick D.W.
        • Aurora S.K.
        • et al.
        Percent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
        J Neurol Neurosurg Psychiatr. 2015; 86: 996-1001
        • Burstein R.
        • Zhang X.C.
        • Levy D.
        • et al.
        Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains.
        Cephalalgia. 2014; 34: 853-869
        • Alam M.
        Pain associated with injection of botulinum a exotoxin reconstituted using isotonic sodium chloride with and without preservative.
        Arch Dermatol. 2002; 138: 510
        • Baizabal-Carvallo J.F.
        • Jankovic J.
        • Pappert E.
        Flu-like symptoms following botulinum toxin therapy.
        Toxicon. 2011; 58: 1-7
        • Silberstein S.D.
        • Dodick D.W.
        • Lindblad A.S.
        • et al.
        Chronic Migraine Treatment Trial Research Group. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine.
        Neurology. 2012; 78: 976-984
        • Boudreau G.P.
        Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study.
        Anesth Pain Res. 2020; 4: 1-4
        • Armanious M.
        • Khalil N.
        • Lu Y.
        • et al.
        Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis.
        J Pain Palliat Care Pharmacother. 2021; 35: 1-6
        • Cohen F.
        • Armand C.
        • Lipton R.B.
        • et al.
        Efficacy and tolerability of calcitonin gene-related peptide targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine.
        Pain Med. 2021; 22: 1857-1863
        • Blumenfeld A.M.
        • Frishberg B.M.
        • Schim J.D.
        • et al.
        Real-World evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review.
        Pain Ther. 2021; 10: 809-826
        • Blazek A.
        • Dafer R.
        • Rhyne C.
        • et al.
        Combined Prophylactic treatment of chronic migraine with OnabotulinumtoxinA and Anti-CGRP monoclonal antibodies (P14-2.001).
        Neurology. 2022; 98: 14
        • Silberstein S.D.
        • Calhoun A.H.
        • Lipton R.B.
        • et al.
        Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study.
        Neurology. 2016; 87: 529-538
        • Yuan H.
        • Chuang T.-Y.
        Update of neuromodulation in chronic migraine.
        Curr Pain Headache Rep. 2021; 25: 71
        • Diener H.-C.
        • Agosti R.
        • Allais G.
        • et al.
        Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.
        Lancet Neurol. 2007; 6: 1054-1062
        • Ching J.
        • Tinsley A.
        • Rothrock J.
        Prognosis following discontinuation of OnabotulinumA Therapy in "Super-responding" Chronic Migraine Patients.
        Headache. 2019; 59: 1279-1285
        • Raffaelli B.
        • Terhart M.
        • Overeem L.H.
        • et al.
        Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.
        Cephalalgia. 2022; 42: 326-334